IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Kindstar Globalgene Technology / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/kindstar-globalgene-technology-inc" target="_blank" data-smartkarma-citation="entities:32175:1" rel="noopener">Kindstar Globalgene Technology (1868874D HK)</a> is a leading independent esoteric clinical testing service provider in China. Kindstar provides full-spectrum testing services primarily to hospitals in various speciality areas, including hematology, genetic diseases and rare diseases, infectious diseases, oncology, neurology and maternity-related diseases. In 2020, Kindstar had a 4.1% revenue market share of the total esoteric testing market in China, according to Frost &amp; Sullivan. Kindstar is set to launch an HKEx IPO to raise around $300 million, according to press reports. Kindstar’s shareholders include Morningside, Investcorp, KPCB, Mayo Clinic and CPE.ICLs (independent clinical laboratory) such as Kindstar provide hospitals with a wide range of testing services that they are not capable of conducting in-house. China’s ICL market consists of routine and esoteric testing. The size of China’s esoteric testing market is forecasted to increase from RMB20,057.6 million in 2020 to RMB27,860.1 million in 2025, representing a CAGR of 6.8% from 2020 to 2025, according to Frost &amp; Sullivan. <div class="content-highlight">Kindstar is well-paced to benefit from this market opportunity as it has the largest esoteric testing portfolio among all the independent esoteric testing providers in China. The business has successfully overcome the negative impact of the COVID-19 pandemic, with most of its segments displaying either a return to growth or lower revenue declines in 4Q20 in comparison to 9M20. In combination, with solid operating leverage and cash generation, we think that the Kindstar IPO is worth a look. </div>

Kindstar Globalgene Technology (1868874D HK) is a leading independent esoteric clinical testing service provider in China. Kindstar provides full-spectrum testing services primarily to hospitals in various speciality areas, including hematology, genetic diseases and rare diseases, infectious diseases, oncology, neurology and maternity-related diseases. In 2020, Kindstar had a 4.1% revenue market share of the total esoteric testing market in China, according to Frost &amp; Sullivan. Kindstar is set to launch an HKEx IPO to raise around $300 million, according to press reports. Kindstar’s shareholders include Morningside, Investcorp, KPCB, Mayo Clinic and CPE.ICLs (independent clinical laboratory) such as Kindstar provide hospitals with a wide range of testing services that they are not capable of conducting in-house. China’s ICL market consists of routine and esoteric testing. The size of China’s esoteric testing market is forecasted to increase from RMB20,057.6 million in 2020 to RMB27,860.1 million in 2025, representing a CAGR of 6.8% from 2020 to 2025, according to Frost &amp; Sullivan. Kindstar is well-paced to benefit from this market opportunity as it has the largest esoteric testing portfolio among all the independent esoteric testing providers in China. The business has successfully overcome the negative impact of the COVID-19 pandemic, with most of its segments displaying either a return to growth or lower revenue declines in 4Q20 in comparison to 9M20. In combination, with solid operating leverage and cash generation, we think that the Kindstar IPO is worth a look. 

Kindstar Globalgene IPO Initiation: Testing, Testing

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Kindstar is a leading esoteric test service provider in China. The company has a dominant market in the independent hematological test segment and is looking to raise up to USD 200m in  H-share listing in Hong Kong. In our previous note, we discussed Kindstar's business segment. The company has a strong footprint in the hematology test segment with the majority of its revenue is derived from the hematological tests, particularly for lymphoma and myeloma related diseases. The company is relatively weak in other areas such as oncology and maternity related businesses. We think the company can continue to grow the existing pie of hematological tests for which the public hospitals do not want to invest in the test equipment and processes but it will be challenging for the company to expand the business into the area where public hospitals are willing to invest in. We think the company has a decent line-up of investors but there is still a lack of international healthcare investors. The management's experience is also decent.In this note, we compare the company's key financial metrics with other leading listed ICL. We also discuss the company's pre-IPO valuation in the context of its growth potential and concerns we raised in our previous note.<h2>Our previous coverage on Kindstar</h2><ul><li><a href="https://www.smartkarma.com/insights/kindstar-pre-ipo-issues-with-scalability" target="_blank" rel="noopener">Kindstar (康圣环球) Pre-IPO: Issues with Scalability</a></li></ul>

Kindstar is a leading esoteric test service provider in China. The company has a dominant market in the independent hematological test segment and is looking to raise up to USD 200m in  H-share listing in Hong Kong. In our previous note, we discussed Kindstar's business segment. The company has a strong footprint in the hematology test segment with the majority of its revenue is derived from the hematological tests, particularly for lymphoma and myeloma related diseases. The company is relatively weak in other areas such as oncology and maternity related businesses. We think the company can continue to grow the existing pie of hematological tests for which the public hospitals do not want to invest in the test equipment and processes but it will be challenging for the company to expand the business into the area where public hospitals are willing to invest in. We think the company has a decent line-up of investors but there is still a lack of international healthcare investors. The management's experience is also decent.In this note, we compare the company's key financial metrics with other leading listed ICL. We also discuss the company's pre-IPO valuation in the context of its growth potential and concerns we raised in our previous note.Our previous coverage on KindstarKindstar (康圣环球) Pre-IPO: Issues with Scalability

Kindstar (康圣环球) Pre-IPO: Is It Worth the Premium?

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Guangzhou Kingmed Diagnostics / Equity Bottom-Up

With the deepening of medical reform and the implementation of hierarchical diagnosis and treatment, medical institutions are facing greater demands for clinical auxiliary diagnosis. At the same time, the DRG (Diagnosis Related Groups) policy has been simulated in 30 pilot cities across the country, and will be implemented in 2021. With the continuous promotion of medical insurance fee control policies such as DRG, the clinical labs in hospitals have been transformed from profit centers to cost centers. As a result, more and more hospitals have begun to consider outsourcing some high-cost inspection projects to independent clinical laboratory (ICL). In ICL, in terms of the current scale, operation capability and the performance in COVID-19, <a href="https://www.smartkarma.com/entities/guangzhou-kingmed-diagnostics" target="_blank" data-smartkarma-citation="entities:30257:1" rel="noopener">Guangzhou Kingmed Diagnostics (603882 CH)</a> and <a href="https://www.smartkarma.com/entities/zhejiang-dian-diagnostics-a" target="_blank" data-smartkarma-citation="entities:19115:1" rel="noopener">Zhejiang Dian Diagnostics A (300244 CH)</a> are top two companies in China. So what is the difference between the two and which one is better?

With the deepening of medical reform and the implementation of hierarchical diagnosis and treatment, medical institutions are facing greater demands for clinical auxiliary diagnosis. At the same time, the DRG (Diagnosis Related Groups) policy has been simulated in 30 pilot cities across the country, and will be implemented in 2021. With the continuous promotion of medical insurance fee control policies such as DRG, the clinical labs in hospitals have been transformed from profit centers to cost centers. As a result, more and more hospitals have begun to consider outsourcing some high-cost inspection projects to independent clinical laboratory (ICL). In ICL, in terms of the current scale, operation capability and the performance in COVID-19, Guangzhou Kingmed Diagnostics (603882 CH) and Zhejiang Dian Diagnostics A (300244 CH) are top two companies in China. So what is the difference between the two and which one is better?

Kingmed Diagnostics (603882 CH) Vs Dian Diagnostics (300244 CH) - Which One Is Better?

Thematic (Sector/Industry)

Compared with developed countries, China's IVD industry started relatively late, and the overall technical level still lags far behind that of developed countries in Europe and America. However, in recent years, with the acceleration of the aging problem and the continuous growth of residents' income, the IVD has become one of the most active and fastest growing industries in China.

Compared with developed countries, China's IVD industry started relatively late, and the overall technical level still lags far behind that of developed countries in Europe and America. However, in recent years, with the acceleration of the aging problem and the continuous growth of residents' income, the IVD has become one of the most active and fastest growing industries in China. 

Industry Report - Insights on China IVD Industry

1. Industry viewpoints:<ul>
<li>The continuous promotion of medical insurance fee control policies such as DRG is conductive to the development of China ICL industry in the future.</li>
<li>For the TAVR industry, the domestic market is still in the early stage of growth, but with a lot of potential in the future.</li>
<li>With the aggravation of population aging and government incentive policies (such as the two-child policy), the assisted reproductive industry in China has been attracting much attention due to its low penetration rate and high gross profit.</li>
</ul>2. Company news:News about the registration of COVID-19 vaccine, updated progress of new drugs and the new agreement of innovative technology platform from <a href="https://www.smartkarma.com/entities/sinopharm-group-co-ltd-h" target="_blank" data-smartkarma-citation="entities:32:1" rel="noopener">Sinopharm Group Co Ltd H (1099 HK)</a>, <a href="https://www.smartkarma.com/entities/shanghai-henlius-biotech-inc" target="_blank" data-smartkarma-citation="entities:27888:1" rel="noopener">Shanghai Henlius Biotech (2696 HK)</a>, <a href="https://www.smartkarma.com/entities/peijia-medical" target="_blank" data-smartkarma-citation="entities:28862:1" rel="noopener">Peijia Medical (9996 HK)</a> and Biocytogen.3. Market review:Last week, stock price for healthcare sector in A share decreased 2.14%, while CSI 300 decreased 3.48% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:
The continuous promotion of medical insurance fee control policies such as DRG is conductive to the development of China ICL industry in the future.
For the TAVR industry, the domestic market is still in the early stage of growth, but with a lot of potential in the future.
With the aggravation of population aging and government incentive policies (such as the two-child policy), the assisted reproductive industry in China has been attracting much attention due to its low penetration rate and high gross profit.
2. Company news:News about the registration of COVID-19 vaccine, updated progress of new drugs and the new agreement of innovative technology platform from Sinopharm Group Co Ltd H (1099 HK), Shanghai Henlius Biotech (2696 HK), Peijia Medical (9996 HK) and Biocytogen.3. Market review:Last week, stock price for healthcare sector in A share decreased 2.14%, while CSI 300 decreased 3.48% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China

Zhejiang Dian Diagnostics Co., Ltd. provides medical diagnostic solutions, as an outsourcer, to various general hospitals, specialized hospitals, community health service centers (stations), township (county) hospitals, medical centers,  disease prevention and control centers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zhejiang Dian Diagnostics A (300244 CH)

Kindstar Globalgene IPO Initiation: Testing, Testing

Kindstar is set to launch an IPO to raise around $300 m. It has successfully overcome the COVID-19 pandemic. In combination, with operating...

Arun George

Kindstar (康圣环球) Pre-IPO: Is It Worth the Premium?

We compare the company's key financial metrics with other leading listed ICL. We also discuss the company's pre-IPO valuation in the context of its...

Ke Yan, CFA, FRM

Kingmed Diagnostics (603882 CH) Vs Dian Diagnostics (300244 CH) - Which One Is Better?

This article analyzed Kingmed and Dian in terms of business scope (no. of labs & testing items...), revenue, profitability, debt...

Xinyao (Criss) Wang

Industry Report - Insights on China IVD Industry

The article analyzed China IVD industry in terms of business mode, trend on efficiency and size of equipment and operation, opportunity in import...

Xinyao (Criss) Wang

China Healthcare Weekly (Dec.11)

The article analyzed industry viewpoints about China ICL industry, TAVR industry and the assisted reproductive industry, and also included...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)